Document Detail

Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation.
MedLine Citation:
PMID:  23614365     Owner:  NLM     Status:  In-Data-Review    
Oncotype DX, a gene-expression profiling assay, provides stratification of patients with estrogen-receptor positive, lymph-node-negative early breast cancer into risk groups based on recurrence score, which are associated with distant recurrence and response to chemotherapy. This study aims to determine whether Oncotype DX influences clinicians' treatment decisions, and whether assay results correlate with histologic assessment. Fifty patients with estrogen-receptor positive, node-negative early breast cancer analyzed by Oncotype DX and operated on by two breast surgeons were included. To assess effect on treatment decisions, clinical vignettes were created by retrospective chart review. Physicians were then presented with the clinical vignettes and instructed to make a treatment decisions (i.e., hormone therapy alone versus hormone therapy combined with chemotherapy) both before and after knowledge of the recurrence score. To assess correlation with histologic assessment, a prospective, blinded review of tumor slides was performed by two pathologists. Based on this review, tumors were placed into low, intermediate and high risk groups for comparison with Oncotype DX assay results. Treatment decisions were changed based on Oncotype DX results in 36 and 18% of cases by breast surgeons and medical oncologists, respectively. All tumors categorized as high risk by Oncotype DX were categorized as high risk based on histologic assessment, and 96% of cases categorized as low risk by recurrence score were categorized as low or intermediate risk by histologic assessment. Oncotype DX significantly influences management of estrogen-receptor positive, lymph-node-negative early breast cancer. Further studies are needed to assess association of histologic categorization to assay results.
Julianne R Biroschak; Gordon F Schwartz; Juan P Palazzo; Adam D Toll; Kristin L Brill; Rebecca J Jaslow; Sun Yong Lee
Related Documents :
24841375 - Male genital reconstruction for the penile cancer survivor.
24789045 - Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment app...
23010705 - Decreased androgen receptor expression is associated with distant metastases in patient...
24551425 - Using multidimensional mutual information to prioritize mammographic features for breas...
12833555 - Attitudes, knowledge, risk perceptions and decision-making among women with breast and/...
18848465 - Microarray methods to identify factors determining breast cancer progression: potential...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The breast journal     Volume:  19     ISSN:  1524-4741     ISO Abbreviation:  Breast J     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505539     Medline TA:  Breast J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  269-75     Citation Subset:  IM    
Copyright Information:
© 2013 Wiley Periodicals, Inc.
Department of Obstetrics and Gynecology, The George Washington University Hospital, Washington, District of Columbia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Morphological distribution and internal enhancement architecture of contrast-enhanced magnetic reson...
Next Document:  Grb10-mediated Negative Regulation of IGF1R-Activated Signalling Pathway Results in Cognitive Disord...